Autres langues Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Produits pharmaceutiques

Marché Fermé - Japan Exchange 08:30:00 14/09/2026			Varia. 5j.	Varia. 1 janv.
5 737,00 ^JPY	+1,25%		-0,28%	+18,66%

17:10	Les actions asiatiques cotées aux États-Unis sous forme d'ADR chutent fortement lors de la séance de lundi	MT
10:58	La FDA accorde un examen prioritaire au Zasocitinib de Takeda Pharmaceutical pour le traitement du psoriasis en plaques	MT

Autres langues

17:10	Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading
10:58	U.S. FDA Grants Priority Review to Takeda Pharmaceutical's Zasocitinib NDA for Plaque Psoriasis
10:46	Takeda's Investigational Plaque Psoriasis Drug Accepted for Priority Review by US FDA
10:20	Takeda Pharmaceutical Company Limited Receives U.S. FDA Acceptance Of New Drug Application Under Priority Review For Zasocitinib In Moderate-To-Severe Plaque Psoriasis
09:01	U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
10/09	Takeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plump
09/09	Takeda Publishes Phase 3 Data Demonstrating Oveporexton Improves Narcolepsy Type 1 Symptoms
09/09	New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
08/09	Pharvaris' genetic disorder drug meets main goal in late-stage trial
04/09	After obesity, pharma seeks its next mega-blockbuster in sleep
04/09	Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing
01/09	Weave Bio and Takeda Enter Collaboration to Deploy Ai-Native Regulatory Automation Across Key Drug Development Activities
31/08	Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House
31/08	Takeda, Other Biotech Firms to Announce New Drug Pricing Deals With White House
31/08	Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says
31/08	Takeda Receives U.S. FDA Approval of MIMRYLO, Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
31/08	Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer
31/08	Takeda Pharmaceutical Wins US Approval for New PV Treatment MIMRYLO
29/08	Takeda Pharmaceutical Company Limited Receives U.S. FDA Approval Of MIMRYLO For Treatment Of Erythrocytosis In Adults With Polycythemia Vera
29/08	Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
28/08	US FDA approves Takeda, Protagonist's drug for rare blood cancer
28/08	Takeda's Mimrylo Gets FDA Approval to Treat Blood Cancer Condition
28/08	Novavax, Inc., Sanofi S.A., And Takeda Pharmaceutical Company Limited Receive Approvals For XFG-Adapted Nuvaxovid Formulation In The U.S., European Union And Japan For 2026-2027 Vaccination Season
28/08	Novavax's Nuvaxovid Approved in US, EU, Japan for 2026-2027 Season
24/08	Takeda Pharmaceutical : Provides Update on ADZYNMA (ADAMTS13, recombinant-krhn)